Cullinan Therapeutics Receives Fast Track Designation for CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

Cullinan Therapeutics has announced that the FDA has granted Fast Track designation to CLN-049 for the treatment of relapsed/refractory acute myeloid leukemia. The company will present data from the Phase 1 clinical trial of CLN-049 at the American Society of Hematology Annual Meeting and Exposition on December 8. This designation provides important momentum for development and allows the company to collaborate closely with the FDA to advance CLN-049 more quickly. Shares of Cullinan Therapeutics are up 2% in pre-market trade on Monday.